NCT06900595 2026-03-18Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical CancerNational Cancer Institute (NCI)Phase 2 Recruiting48 enrolled